Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Sangart has started testing its lead product, Hemospan, in a single-blind, placebo-controlled Phase II clinical study involving chronic critical limb ischemia patients.
Subscribe to our email newsletter
The study at the Karolinska Institute in Stockholm, Sweden is designed to evaluate the safety and efficacy of Hemospan in patients suffering from chronic critical limb ischemia (CCLI), a debilitating condition that results from severely limited blood circulation to the legs. The primary endpoint is tissue oxygenation measured noninvasively.
Robert Winslow, chairman, president and CEO of Sangart, said: “The goal of this study is to demonstrate that Hemospan can increase oxygen supply to severely compromised tissue, conclusively establishing it as an oxygen-carrying plasma expander.”